Gadopentetate dimeglumine-enhanced three-dimensional MR-angiography: dosing, safety, and efficacy.
Noninvasiveness, inherent three-dimensionality allowing reformations in any desired plane, and safe contrast agents, coupled with high diagnostic accuracy have driven the rise in popularity of contrast-enhanced MR angiography (CE-MRA) within the medical community. Reflecting its dominant market share as a paramagnetic contrast agent, gadopentetate dimeglumine (Gd-DTPA) has been used for the majority of clinically-performed MRA exams. Over the period January 1994 to February 2002, a total of 172 original studies describing the use of gadolinium-enhanced MRA in more than three human subjects were identified. Of these, 117 described the use of Gd-DTPA as the contrast agent for MRA. A total of 4046 subjects who received Gd-DTPA for MRA are described in these studies. Analysis of these data demonstrate Gd-DTPA to be a safe contrast agent for MRA when applied in a dose ranging from 0.1 to 0.3 mmol/kg of bodyweight. The documented clinical results show Gd-DTPA to be efficacious in the assessment of the arterial system. The effectiveness of Gd-DTPA-enhanced MRA extends beyond the detection, localization, and characterization of arterial disease, and encompasses choice and planning of appropriate therapy, as well as evaluation of therapeutic effectiveness.
Department of Diagnostic and Interventional Radiology, University Hospital Essen, Essen, Germany. mathias.goyen@uni-essen.de
Mathias
M
Goyen
Jörg F
JF
Debatin
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000175:diagnosis*; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D019786:Gadolinium DTPA / Q000009:adverse effects; D006801:Humans; D021621:Imaging, Three-Dimensional / Q000379:methods*; D018810:Magnetic Resonance Angiography / Q000379:methods*; D008875:Middle Aged
D003287:Contrast Media; D019786:Gadolinium DTPA